Comparision Of Effects On Different Doses Of Rosuvastatin Before Percutaneous Coronary Intervention In Patients With Acute Coronary Syndrome

Objective：To compare the efficacy of rosuvastatin20mg versus10mg beforepercutaneous coronary intervention(PCI) in patients with acute coronarysyndrome(ACS).Methods：Consecutive140patients with ACS who underwent PCI were randomlyassigned to receive10mg rosuvastatin daily (standard group,n=70) or to receive20mg rosuvastatin daily (intensive group, n=70) from December2011to September2012.Rosuvastatin treatment is initiated immediately during hospitalization.Theincidence of major adverse cardiac events (MACE) and adverse drug reactions wasassessed after30days.Serum levels of chemerin, creatine kinase-myocardial band(CK-MB), and cardiac troponin I (cTnI) were detected before PCI and24hours afterPCI.Results：30-day incidence of MACE occurred in10.7%of all patients,14.3%ofpatients in the standard group and7.1%of patients in the intensive group(p=0.223).The incidence of peri-procedural myocardial injury occurred in21.4%ofall patients,17.1%of patients in the standard group and25.7%of patients in theintensive group (p=0.217).Serum chemerin levels were significantly decreased24hours after PCI in the both groups(p=0.001and p=0.000).Serum chemerin levelswere significantly lower24hours after PCI in the intensive group compared with inthe standard group(p=0.03).Conclusion：The30-day incidence of MACE and the incidence of peri-proceduralmyocardial injury in patients with ACS who underwent PCI were not significantlydifferent between the standard group and the intensive group of Rosuvastatin.Serum chemerin levels were significantly decreased24hours after PCI in the both groupsand were significantly lower in the intensive group.